We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

MRI Dye Technique Could Detect HIV Dementia

By MedImaging International staff writers
Posted on 07 Mar 2016
A new magnetic resonant imaging (MRI) contrast dye could be used to target specific white blood cells (WBCs) believed to play a key role in the development of HIV-associated neurocognitive disorders (HAND).

Researchers at the University of Hawaii (Honolulu, USA) are conducting studies to examine the use of ferumoxytol—an ultra-small iron oxide MRI contrast agent—to identify and quantitate monocyte/macrophage (M/MΦ)-mediated inflammation in the brain of HIV-infected people. M/MΦs are believed to play a critical role in the pathogenesis of HAND, but neuroimaging HIV research has not as yet focused on assessing M/MΦ-mediated inflammation in the brain, since no modality exists that can define inflammation extent as a diagnostic tool, or assist in defining objective improvement in clinical trials addressing HAND.

Image: MRI of the brain before (A) and after (B) ferumoxytol injection. A magnified image (C) demonstrates ferumoxytol accumulation (Photo courtesy of the University of Hawaii).
Image: MRI of the brain before (A) and after (B) ferumoxytol injection. A magnified image (C) demonstrates ferumoxytol accumulation (Photo courtesy of the University of Hawaii).

The researchers hypothesized that imaging based on ferumoxytol, which is avidly taken up by circulating M/MΦs, could identify ongoing inflammation resulting from the perivascular M/MΦ, a key pathologic correlate of HAND. The neurocognitive disorders in HIV continue to be prevalent, despite effective combination antiretroviral therapy (cART), and are responsible for a significant impact on morbidity and quality of life. The researchers believe that once M/MΦs have switched on to battle HIV, an unintended consequence is the production of toxic chemicals in the brain that cause uncontrolled inflammation and ultimately cognitive impairment.

“Four HIV-infected subjects with undetectable HIV RNA levels on antiretroviral therapy and cognitive impairment underwent ferumoxtyol-enhanced brain MRI,” wrote lead investigator Neurologist Beau Nakamoto, MD, PhD, in a 2013 study. “On post-ferumoxytol susceptibility-weighted images, all HIV-infected subjects demonstrated a diffuse “tram track” appearance in the perivascular regions of cortical and deep white matter vessels, suggesting ferumoxytol uptake in monocytes/macrophages. This finding was not present in a HIV-seronegative control.”

Related Links:

University of Hawaii



Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Ultrasound System
Voluson Signature 18
New
Ultrasound Table
Ergonomic Advantage (EA) Line
Brachytherapy Planning System
Oncentra Brachy

Latest MRI News

Diamond Dust Could Offer New Contrast Agent Option for Future MRI Scans

Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients

PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients